List of Excipients in Branded Drug TAMSULOSIN HYDROCHLORIDE

« Back to Dashboard

Generic Drugs Containing TAMSULOSIN HYDROCHLORIDE

Company	Ingredient	NDC	Excipient
Amneal Pharmaceuticals of New York LLC	tamsulosin hydrochloride	0115-8211	AMMONIA
Amneal Pharmaceuticals of New York LLC	tamsulosin hydrochloride	0115-8211	COPOVIDONE K25-31
Amneal Pharmaceuticals of New York LLC	tamsulosin hydrochloride	0115-8211	D&C RED NO. 28
Amneal Pharmaceuticals of New York LLC	tamsulosin hydrochloride	0115-8211	D&C YELLOW NO. 10

What are the Most Frequently-Used Excipients in TAMSULOSIN HYDROCHLORIDE?

# Of NDCs	Excipient
54	ALCOHOL
49	AMMONIA
2	AMMONIUM CATION
55	BUTYL ALCOHOL

Tamsulosin Hydrochloride Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Tamsulosin hydrochloride is a mature, genericized alpha-1A adrenergic receptor antagonist used primarily for benign prostatic hyperplasia (BPH). The main commercial opportunity is not basic API exclusivity. It is differentiated modified-release delivery, supply-chain optimization, improved swallowability, and formulations that preserve the drug’s food-effect and dissolution profile while reducing manufacturing cost.

The strongest development path is a multiparticulate modified-release capsule or capsule-compatible granule system using established excipients. New tablets, orally disintegrating products, sprinkle formulations, and combination products may create commercial differentiation, but they carry higher bioequivalence, food-effect, and intellectual-property risk.

What is tamsulosin hydrochloride and how is it formulated?

Tamsulosin hydrochloride is the hydrochloride salt of tamsulosin, marketed originally as Flomax in a modified-release oral capsule. The labeled strengths are 0.4 mg and 0.8 mg, with the 0.8 mg dose generally used after inadequate response or tolerability assessment at 0.4 mg [1].

The reference product uses modified-release pellets contained in a hard gelatin capsule. A pellet-based design separates drug loading from release control and allows the manufacturer to tune dissolution through coating thickness, polymer selection, pellet size, and coating process parameters.

Reference-product formulation architecture

Public labeling identifies excipient classes associated with the Flomax capsule, including:

• Microcrystalline cellulose
• Methacrylic acid copolymer
• Talc
• Triethyl citrate
• Polysorbate 80
• Sodium lauryl sulfate
• Gelatin
• Titanium dioxide
• Colorants, including iron oxide and FD&C Yellow No. 6, depending on capsule component and strength [1]

The exact composition and manufacturing process may differ among marketed products. A generic manufacturer must establish pharmaceutical equivalence and bioequivalence to the listed drug, not necessarily duplicate every excipient or process step.

Which excipients are most important for tamsulosin modified release?

The critical excipient decision is the release-control system. Tamsulosin is administered at a very low dose, so content uniformity and drug distribution are as important as dissolution control.

Formulation function	Typical excipient classes	Primary development concern
Core diluent and pellet former	Microcrystalline cellulose, sugars, starch-based materials	Pellet strength, drug distribution, friability
Binder	Hypromellose, povidone, copovidone	Granulation behavior and content uniformity
Release-control polymer	Methacrylic acid copolymers, ethylcellulose, hypromellose-based systems	Dissolution profile and pH sensitivity
Plasticizer	Triethyl citrate, polyethylene glycol	Film flexibility, coating defects, storage stability
Anti-tacking agent	Talc, colloidal silicon dioxide	Coating efficiency and agglomeration
Surfactant or wetting agent	Polysorbate 80, sodium lauryl sulfate	Drug wetting, coating uniformity, dissolution reproducibility
Capsule shell	Gelatin or hypromellose	Moisture transfer, shell integrity, patient acceptability
Lubricant	Magnesium stearate, sodium stearyl fumarate	Ejection force and dissolution impact
Colorant and opacifier	Titanium dioxide, iron oxides, approved dyes	Product identification and regulatory compliance

A low-dose drug magnifies small process deviations. The development team should prioritize blend uniformity, pellet assay, pellet-size distribution, coating weight gain, and capsule fill-weight control.

Why methacrylic acid copolymers matter

Methacrylic acid copolymers can provide pH-dependent release control. Their use may support delayed or sustained release, but the target profile must match the reference product across relevant dissolution media. A polymer system that performs well in a single buffer can fail under biorelevant or fed-state conditions.

Why triethyl citrate and talc matter

Triethyl citrate plasticizes the polymer film and reduces cracking during drying, handling, and storage. Talc reduces pellet adhesion during coating. Excessive talc can alter film permeability and create batch-to-batch dissolution variability.

Why surfactant selection matters

Polysorbate 80 and sodium lauryl sulfate can improve wetting and coating uniformity. They can also change dissolution kinetics, interact with capsule materials, and create stability issues through oxidation or peroxide formation. Supplier grade, peroxide limits, and storage conditions should be controlled in the finished-product specification.

What excipient strategies create commercial opportunities?

1. Generic multiparticulate capsule

The lowest-risk opportunity is a conventional modified-release capsule with a reference-like dissolution profile. Competitive advantages can come from:

• Lower coating-material consumption
• Higher pellet yield
• Shorter coating cycles
• Reduced solvent use
• Improved content-uniformity capability
• Lower capsule-filling losses
• Dual sourcing of critical excipients

The product should remain close to the reference product in release behavior. Excipients that materially change release, food effect, or absorption may trigger additional regulatory requirements.

2. Sprinkle capsule or opened-capsule product

A capsule that can be opened and sprinkled onto soft food could address patients with swallowing difficulty. This is a meaningful product concept only if the pellets remain intact and the labeling supports the administration method.

The critical tests include:

• Pellet recovery after capsule opening
• Dose uniformity after sprinkling
• Stability on the selected food vehicle
• Chewing resistance
• In-vitro dissolution after administration
• Bioequivalence under relevant conditions

The pellets must not be crushed or chewed if crushing changes the release profile. A sprinkle claim would require clear administration instructions and supporting clinical or pharmacokinetic data.

3. Orally disintegrating tablet

An orally disintegrating tablet could improve administration convenience. The formulation challenge is that rapid tablet disintegration must not produce immediate release of tamsulosin if the reference product is modified release.

Potential approaches include:

• Coated modified-release microparticles compressed into a tablet
• Drug-loaded ion-exchange particles
• Multiparticulates embedded in a rapidly disintegrating matrix
• Taste-masked coated drug particles

The main risks are coating damage during compression, dose dumping, moisture sensitivity, and bioequivalence failure. An ODT is more likely to require a formulation-specific regulatory strategy than a conventional capsule.

4. Low-cost excipient replacement

Replacing branded or specialty excipients with compendial alternatives can improve margins. The most practical substitutions involve:

• Equivalent grades of microcrystalline cellulose
• Alternative methacrylic acid copolymer grades with matched release behavior
• Alternative plasticizers
• Reduced or substituted surfactant systems
• Hypromellose capsule shells instead of gelatin

The commercial value depends on demonstrating that the replacement does not affect dissolution, stability, capsule performance, or bioequivalence. The lowest-risk substitutions are those made within the same functional class and supported by comparative supplier data.

5. Fixed-dose or co-packaged BPH products

Tamsulosin can be commercially paired with other BPH therapies, particularly 5-alpha-reductase inhibitors. Combination products face formulation and regulatory complexity because the pharmacokinetic profiles, dose strengths, labeling, and patent positions of both active ingredients must be evaluated.

A co-packaged product may provide a simpler route than a fixed-dose tablet. A fixed-dose combination requires compatibility studies, dose-selection justification, manufacturing controls, and a combined clinical rationale.

When does tamsulosin lose exclusivity?

Tamsulosin has lost its principal small-molecule exclusivity. The original Flomax product was approved by the FDA in 1997, and generic tamsulosin hydrochloride products entered the U.S. market after the relevant brand protections expired [1, 2].

Milestone	Status
Original U.S. approval	FDA approval of Flomax in 1997
Active ingredient	Tamsulosin hydrochloride
Regulatory pathway for competitors	Abbreviated New Drug Application, generally
Original product exclusivity	Expired
Core active-ingredient patent position	Expired
Current competitive basis	Price, supply reliability, formulation, channel access, and dosage convenience

The Orange Book remains the controlling source for current listed patents and regulatory exclusivity. Tamsulosin is a mature product with multiple approved generic manufacturers, and no broad, commercially meaningful active-ingredient exclusivity is expected to block ordinary generic entry [2].

What patents protect tamsulosin hydrochloride products?

The historical patent estate covered the tamsulosin compound, pharmaceutical compositions, and modified-release products. Those foundational rights have expired or ceased to provide a practical barrier to standard generic capsules.

Current patent risk is more likely to arise from:

• A specific modified-release architecture
• A novel pellet-coating sequence
• A differentiated capsule or tablet design
• A fixed-dose combination
• A new method of use
• Manufacturing processes with unusually narrow claim scope
• Device or packaging claims associated with a delivery system

A developer should distinguish between a patent that appears in a historical patent family and a patent that is currently enforceable, listed in the Orange Book, and commercially relevant to the intended dosage form.

What is the Orange Book status of tamsulosin?

Tamsulosin hydrochloride capsules are approved through ANDAs and the original NDA. The Orange Book should be reviewed for current patent listings, therapeutic equivalence codes, dosage forms, and reference-listed-drug status [2].

For a conventional 0.4 mg or 0.8 mg generic capsule, the practical regulatory path is an ANDA supported by comparative dissolution and bioequivalence. A novel dosage form or materially different delivery system may require a 505(b)(2) application rather than a standard ANDA.

Which companies are challenging or competing with Flomax?

The U.S. tamsulosin market includes multiple generic manufacturers and distributors. The competitive field has historically included large generic companies such as Teva, Sandoz, Mylan/Viatris, Dr. Reddy’s, Lupin, Zydus, and others, subject to changing marketing status and supply arrangements.

The competition is primarily commercial rather than litigation-driven. The main variables are:

• Wholesale acquisition cost and contract pricing
• Pharmacy benefit-manager placement
• Manufacturing reliability
• Ability to supply both 0.4 mg and 0.8 mg strengths
• Capsule and bottle configurations
• Recall history
• API sourcing
• Customer concentration

A new entrant is unlikely to win solely through another conventional capsule. A differentiated excipient system must produce a measurable benefit or a structurally lower cost of goods.

Are Paragraph IV challenges relevant to tamsulosin?

Paragraph IV litigation was more relevant during the original generic-entry period, when competitors challenged listed patents covering Flomax or related formulations. For current development, the main question is whether any unexpired, listed patent covers the proposed product.

For a standard tamsulosin modified-release capsule, the expected Paragraph IV risk is lower than for a recently approved product. A new formulation may create a new patent target, but it may also create its own freedom-to-operate exposure if it reads on another company’s formulation claims.

The ANDA filing strategy should include:

1. Orange Book patent review.
2. Patent-family analysis for formulation and manufacturing claims.
3. Claim-chart review against the proposed excipient system.
4. Certification strategy under 21 U.S.C. § 355(j).
5. Assessment of a potential 30-month stay if a listed patent is challenged.

What formulation patents could protect a new tamsulosin product?

A differentiated formulation patent would need claims tied to a specific technical structure or performance result. Potential claim categories include:

• Tamsulosin-loaded pellets with defined particle-size ranges
• A particular polymer-to-drug ratio
• A defined coating weight gain
• A specified dissolution profile
• A low-dose multiparticulate tablet
• A capsule that supports sprinkle administration
• A formulation with reduced food effect
• A moisture-stable capsule shell and pellet combination
• A fixed-dose combination with defined release characteristics

Claims based only on substituting one routine excipient for another may face obviousness challenges. Stronger protection generally requires a defined formulation architecture combined with comparative data showing an unexpected dissolution, stability, bioavailability, or manufacturing result.

What FDA regulatory pathway applies to new tamsulosin formulations?

Conventional generic capsule

A conventional capsule generally proceeds through an ANDA. The applicant must demonstrate pharmaceutical equivalence and bioequivalence to the reference listed drug. FDA guidance for tamsulosin should be reviewed for product-specific recommendations, including strength, fed and fasting studies, and dissolution expectations [3].

Novel dosage form

An ODT, sprinkle product, tablet, liquid, or combination product may require a 505(b)(2) application if the product cannot rely fully on the reference product’s safety and efficacy findings. The route depends on the extent of formulation and labeling differences.

FDA bioequivalence considerations

The development program should evaluate:

• 0.4 mg and 0.8 mg strengths
• Fasting and fed administration
• Single-dose pharmacokinetics
• AUC and Cmax
• Dose proportionality where applicable
• Alcohol-induced dose dumping
• Comparative dissolution across multiple pH conditions
• Stability through the proposed shelf life

Tamsulosin’s labeled administration after the same meal each day reflects the importance of consistent food exposure. A formulation that materially changes food effect is a regulatory and commercial risk [1].

What manufacturing and IP barriers affect tamsulosin products?

The largest manufacturing barrier is not chemical synthesis. It is consistent production of a low-dose modified-release multiparticulate product.

Key barriers include:

• Uniform deposition of a very low drug load
• Pellet-size control
• Reproducible polymer coating
• Prevention of pellet agglomeration
• Capsule-fill-weight control
• Avoidance of coating damage during handling
• Control of residual solvents or coating-process impurities
• Moisture protection
• API and excipient supply qualification

API manufacturing is mature, but source changes can alter particle size, polymorphic form, bulk density, assay, or impurity profile. These changes may affect pellet manufacture and dissolution even when the API meets compendial specifications.

How strong is the patent estate for tamsulosin?

The foundational tamsulosin patent estate is weak as a current barrier because the core compound and original product protections are expired. New formulation patents may have moderate value if they cover a technically difficult release system, a commercially important administration method, or a measurable reduction in food effect.

Patent strength should be assessed across four dimensions:

Dimension	Assessment
Core compound protection	Expired
Standard capsule protection	Limited practical barrier
Novel delivery systems	Potentially protectable
Method-of-use claims	Possible, but narrower and more vulnerable to design-around

A formulation patent has greater commercial value when it protects a product that is difficult to reproduce using routine excipient substitution.

What generic launch scenarios exist?

Scenario 1: Standard 0.4 mg capsule

This is the lowest regulatory risk and highest price-competition scenario. The product requires efficient manufacturing and dependable supply. Margins may be thin unless the entrant has a cost advantage or a strong distribution position.

Scenario 2: 0.4 mg and 0.8 mg dual-strength launch

Offering both strengths improves pharmacy coverage and prescriber continuity. It also increases manufacturing complexity, inventory requirements, and quality-control workload.

Scenario 3: Sprinkle or swallow-friendly product

This creates patient-convenience differentiation but requires additional development work. The commercial opportunity is strongest in long-term-care, geriatric, and home-health channels.

Scenario 4: ODT or novel tablet

This may support premium positioning, but the formulation must preserve modified release and demonstrate acceptable pharmacokinetics. It is a higher-risk 505(b)(2) or formulation-specific program.

Scenario 5: Combination product

The opportunity is larger if the product simplifies polypharmacy, but regulatory, clinical, patent, and reimbursement requirements are substantially higher.

How does tamsulosin compare with other BPH drugs?

Product	Drug class	Typical formulation opportunity	Patent and competition profile
Tamsulosin	Alpha-1A antagonist	Multiparticulate modified release, sprinkle, ODT	Mature generic market
Silodosin	Alpha-1A antagonist	Modified-release capsule, dose optimization	Newer estate historically, but generic competition developing
Alfuzosin	Alpha blocker	Extended-release tablet	Mature generic market
Finasteride	5-alpha-reductase inhibitor	Tablet and combinations	Mature generic market
Dutasteride	5-alpha-reductase inhibitor	Soft-gel capsule and combinations	More formulation-specific considerations
Tadalafil	PDE-5 inhibitor	Tablet, combination, adherence products	Broader lifestyle and BPH positioning

Tamsulosin has a strong formulation-development advantage because its commercial history establishes a known multiparticulate modified-release format. Its disadvantage is intense price competition.

What revenue exposure and commercial value can a new excipient strategy create?

Revenue exposure depends on the target channel rather than on broad market growth. A conventional U.S. generic entrant may face rapid price erosion. A differentiated product can pursue higher-value segments:

• Long-term-care dispensing
• Medicare and managed-care contracts
• Mail-order pharmacy
• International markets with fewer competitors
• Patients with swallowing difficulty
• Combination-treatment channels
• Private-label and contract-manufacturing arrangements

The most defensible value proposition is usually lower total manufacturing cost or improved administration. A minor excipient change without a patient, payer, or manufacturing benefit is unlikely to support premium pricing.

Key Takeaways

• Tamsulosin hydrochloride is a mature generic drug with expired foundational compound protection.
• The reference formulation is a modified-release multiparticulate capsule.
• Microcrystalline cellulose, methacrylic acid copolymers, talc, triethyl citrate, surfactants, and capsule-shell materials are central to product performance.
• The lowest-risk development path is a conventional 0.4 mg and 0.8 mg generic capsule with a reference-like dissolution profile.
• Sprinkle, ODT, tablet, and combination products provide greater differentiation but carry higher bioequivalence and regulatory risk.
• Formulation patents can protect defined pellet structures, coating systems, dissolution profiles, and administration methods.
• Standard generic competition is primarily a cost, supply, and contracting business.
• A successful excipient strategy should produce either lower cost of goods, improved patient administration, or a measurable pharmacokinetic or stability advantage.

FAQs

Can tamsulosin hydrochloride be formulated as an immediate-release tablet?

Yes, but an immediate-release tablet would not automatically be equivalent to the modified-release reference product. It may require a different regulatory pathway, new pharmacokinetic data, and careful assessment of adverse-event and food-effect differences.

Which excipient is most likely to control tamsulosin release?

The release-control polymer system, often based on a methacrylic acid copolymer or another polymer coating, is usually more important than the filler. Coating composition, weight gain, porosity, and process conditions collectively determine release.

Can tamsulosin capsules be opened and sprinkled on food?

This depends on the specific product labeling. A sprinkle claim requires product-specific evidence showing that opening the capsule and administering intact pellets does not alter dose delivery or release. Patients should not assume that an unlabeled capsule can be opened or crushed.

Is a tamsulosin fixed-dose combination commercially attractive?

It can be attractive where patients commonly receive multiple BPH medicines, but development must address compatibility, dose selection, labeling, reimbursement, and the patent status of every active ingredient and formulation component.

Are excipient substitutions sufficient to obtain a new tamsulosin patent?

Usually not by themselves. A stronger patent position generally requires a defined formulation architecture and evidence of an unexpected technical result, such as improved stability, reduced food effect, controlled dissolution, or superior manufacturing performance.

References

1. U.S. Food and Drug Administration. (2023). Flomax (tamsulosin hydrochloride) prescribing information. DailyMed.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book.

3. U.S. Food and Drug Administration. (2024). Product-specific guidance for tamsulosin hydrochloride oral capsules. Center for Drug Evaluation and Research.

4. U.S. Food and Drug Administration. (2018). Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. Guidance for Industry.

5. U.S. Food and Drug Administration. (1997). Flomax approval history and regulatory review materials. Drugs@FDA.